Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
Future direction: Multi target combination and cell therapy To overcome current limitations, the "central plan" intervention for GLP-1RA is moving towards the following directions: Multi target agonist development GLP-1/GIP/GCGR triple target agonists (such as Retatrutide) have entered phase III clinical trials, and their weight loss effect is expected to reach 22% -24%
W., Astrup, A., Hjorth, M
You won't know the exact dose you're administering, making your results impossible to replicate
This GLP-1 receptor assay is suitable for compound profiling studies as well as high throughput screening campaigns with proven high sensitivity to the GLP-1 (7-36) reference ligand and robustness
US$ 20.70
US$ 20.50
US$ 22.05
US$ 28.25
US$ 29.39
